目的 探討泌石通膠囊聯(lián)合坦索羅辛治療輸尿管末端結(jié)石的臨床療效。方法 收集2015年2月-2017年2月在南陽(yáng)市中心醫(yī)院進(jìn)行治療的輸尿管末端結(jié)石患者82例，根據(jù)用藥的差別分為對(duì)照組（41例）和治療組（41例）。對(duì)照組口服鹽酸坦索羅辛緩釋膠囊，0.4 mg/次，1次/d；治療組在對(duì)照組的基礎(chǔ)上口服泌石通膠囊，0.9 g/次，2次/d。兩組均經(jīng)過2周治療。評(píng)價(jià)兩組患者臨床療效，同時(shí)比較治療前后兩組患者最大尿流率、結(jié)石排出時(shí)間以及QOL和VAS評(píng)分差異。結(jié)果 治療后，對(duì)照組的臨床總有效率為80.49%，顯著低于治療組的95.12%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者最大尿流率顯著升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組患者最大尿流率、結(jié)石排出時(shí)間和排石率均明顯好于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者QOL和VAS評(píng)分均明顯下降，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組比對(duì)照組降低更顯著，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 泌石通膠囊聯(lián)合坦索羅辛治療輸尿管末端結(jié)石可有效減輕患者痛苦，提高患者生活質(zhì)量，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To evaluate the clinical efficacy of Mishitong Capsules combined with tamsulosin in treatment of distal ureteral stone. Methods Patients (82 cases) with distal ureteral stone in Nanyang City Center Hospital from February 2015 to February 2017 were divided into control (41 cases) and treatment (41 cases) groups based on different treatments. Patients in the control group were po administered with Tamsulosin Hydrochloride Sustained Release Capsules, 0.4 mg/time, once daily. Patients in the treatment group were po administered with Mishitong Capsules on the basis of the control group, 0.9 g/time, twice daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the difference of maximum urinary flow rate, stone expulsion time, QOL and VAS scores in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control group was 80.49%, which was significantly lower than 95.12% in the treatment groups, and there were differences between two groups (P<0.05). After treatment, the maximum urinary flow rate in two groups was significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, the maximum urinary flow rate, stone expulsion time and rate in the treatment group were obviously better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the QOL and VAS scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the scores in the treatment group were obviously lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Mishitong Capsules combined with tamsulosin can effectively relieve the pain and improve the quality of life in treatment of distal ureteral stone, which has a certain clinical application value.